Scleroderma Clinical Trials

Find Scleroderma Clinical Trials Near You

Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis: A Prospective, Randomized, Multicenter Superiority Trial

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug, Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This prospective, randomized, blinded, multicenter clinical study aims to evaluate the safety and efficacy of autologous adipose-derived regenerative cells (ADRCs) in improving hand dysfunction in patients with systemic sclerosis (SSc). The study plans to enroll 48 eligible patients, randomly assigned to two groups. The experimental group will receive ADRCs, prepared from the Celution system, which is injected into specific sites on each finger of both hands. The control group will receive standard care according to established treatment guidelines. The primary endpoint is the change from baseline in the Cochin Hand Function Scale (CHFS) score at 24 weeks. Secondary endpoints include assessments of skin thickness, Raynaud phenomenon, hand strength, quality of life, pain, and other measures at various time points. Safety and device performance will be monitored throughout the study. This investigation seeks to explore a new potential therapeutic direction for managing hand dysfunction in systemic sclerosis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Age 18-70 years old (inclusive), gender not restricted;

• According to the 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) systemic sclerosis (SSc) diagnostic criteria, diagnosed as diffuse cutaneous type or localized cutaneous type;

• Thickened hand skin, modified Rodnan skin score ≥ 8 points and ≤ 35 points;

• Cochin Hand Function Scale (CHFS) ≥ 20 (total score 90), with or without skin ulcers;

• Capable of safely undergoing liposuction to obtain sufficient adipose tissue (the preferred fat extraction sites are the abdomen, followed by the lateral abdomen, inner and outer thighs, posterior thighs, and anterior thighs; multiple sites can be selected for liposuction to obtain sufficient adipose tissue);

• Voluntary participation in this clinical trial and signing the informed consent form by the subject.

Locations
Other Locations
China
NanFang Hospital of Southern Medical University
RECRUITING
Guangzhou
Huashan Hospital Fudan University
RECRUITING
Shanghai
Time Frame
Start Date: 2025-12-31
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 48
Treatments
Experimental: ADRCs group
Other: Standard Treatment group
Related Therapeutic Areas
Sponsors
Collaborators: Nanfang Hospital, Southern Medical University, Huashan Hospital
Leads: Cytori Therapeutics

This content was sourced from clinicaltrials.gov